{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:24:19Z","timestamp":1787502259526,"version":"build-2736575974"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>Neuroblastoma is the most prevalent extracranial solid tumor in infancy and early childhood, accounting for 8%\u201310% of all pediatric malignancies and contributing significantly to cancer-related mortality. Its clinical spectrum ranges from spontaneous regression to aggressive metastatic disease, often influenced by underlying genetic aberrations such as MYCN amplification and chromosomal deletions (1p, 11q, and 17q). We present a rare case of a full-term male neonate diagnosed with stage 4 neuroblastoma originating from the left adrenal gland, exhibiting both MYCN amplification and 1p deletion. The patient had extensive liver metastases and supradiaphragmatic lymphadenopathy at diagnosis. Multimodal treatment, including intensive chemotherapy per the NB2004 protocol, surgical resection, high-dose consolidation chemotherapy, and autologous hematopoietic stem cell transplantation (AHSCT), led to complete remission by 11 months of age. Despite severe post-transplant complications such as sepsis and enteropathy, the patient remained disease-free with normal developmental milestones at follow-up. To the best of our knowledge, this is the first reported case of neonatal neuroblastoma with concurrent MYCN amplification and 1p deletion achieving favorable outcome through comprehensive multimodal therapy. This case underscores the importance of early diagnosis, genetic profiling, and aggressive treatment in managing high-risk neuroblastoma in neonates.<\/jats:p>","DOI":"10.3389\/fped.2025.1641407","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:52Z","timestamp":1768372912000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Complete remission in a neonate with high-risk neuroblastoma harboring MYCN amplification and 1p deletion: a case for aggressive early intervention, and literature review"],"prefix":"10.3389","volume":"13","author":[{"given":"N. Kh.","family":"Gabitova","sequence":"first","affiliation":[{"name":"Pediatrics Department, Kazan State Medical University","place":["Kazan, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. N.","family":"Cherezova","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Kazan State Medical University","place":["Kazan, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. V.","family":"Osipova","sequence":"additional","affiliation":[{"name":"Pediatric Department of the State Autonomous Heath Institution, Children\u2019s Republican Clinical Hospital (CPCH)","place":["Kazan, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. I.","family":"Sadykova","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Kazan State Medical University","place":["Kazan, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalal","family":"Nasr","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Kids Heart Medical Center Abu Dhabi","place":["Abu Dahbi, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman A.","family":"Gobarah","sequence":"additional","affiliation":[{"name":"Pediatric Department Faculty of Medicine, Suez Canal University","place":["Ismailia, Egypt"]},{"name":"Pediatrics Department, Dubai Academic Health Corporation","place":["Dubai, United Arab Emirates"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Arafat","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Kazan State Medical University","place":["Kazan, Russia"]},{"name":"Pediatrics Department, Jiahui International Hospital","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"B1","article-title":"Key Statistics About Neuroblastoma","year":""},{"key":"B2","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1200\/JCO.2008.16.6785","article-title":"The international neuroblastoma risk group (INRG) classification system: an INRG task force report","volume":"27","author":"Cohn","year":"2009","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrc1014","article-title":"Neuroblastoma: biological insights into a clinical enigma","volume":"3","author":"Brodeur","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1186\/s12885-024-13044-5","article-title":"Event-free survival in neuroblastoma with MYCN amplification and deletion of 1p or 11q may be associated with altered immune status","volume":"24","author":"Wei","year":"2024","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.4103\/jfmpc.jfmpc_992_23","article-title":"Neonatal neuroblastoma presenting as recurrent chylothorax in a hydropic baby: a case report","volume":"13","author":"Alhazmi","year":"2024","journal-title":"J Family Med Prim Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40880-019-0409-1","article-title":"Deletion of chromosome 11q23 band predicts poor prognosis in patients with metastatic neuroblastoma in the bone marrow without MYCN amplification","volume":"39","author":"Yue","year":"2019","journal-title":"Cancer Commune (London)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1200\/JCO.2010.34.3392","article-title":"Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the international neuroblastoma risk group project","volume":"29","author":"London","year":"2011","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"612518","DOI":"10.3389\/fcell.2021.612518","article-title":"A chemo-genomic approach identifies diverse epigenetic therapeutic vulnerabilities in MYCN-amplified neuroblastoma","volume":"9","author":"Krstic","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1056\/NEJM199910143411601","article-title":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children\u2019s cancer group","volume":"341","author":"Matthay","year":"1999","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1038\/s41409-021-01303-z","article-title":"Effect of high-dose chemotherapy plus stem cell rescue on the survival of patients with neuroblastoma modified by MYCN gene gain\/amplification and remission status: a nationwide registration study in Japan","volume":"56","author":"Saito","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/bjc.2012.375","article-title":"Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project","volume":"107","author":"Schleiermacher","year":"2012","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMoa052399","article-title":"Chromosome 1p and 11q deletions and outcome in neuroblastoma","volume":"353","author":"Attiyeh","year":"2005","journal-title":"N Engl J Med"},{"key":"B13","article-title":"NB2004 Trial Protocol for Risk Adapted Treatment of Children with Neuroblastoma Principal investigator [Electronic resource]","author":"Berthold","year":"2004"},{"key":"B14","article-title":"Neuroblastoma Treatment (PDQ\u00ae) \u2013 Health Professional Version","year":"2024"},{"key":"B15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/nature07261","article-title":"Identification of ALK as a major familial neuroblastoma predisposition gene","volume":"455","author":"Moss\u00e9","year":"2008","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1\/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/pbc.24713","article-title":"Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy","volume":"61","author":"Valteau-Couanet","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrc3526","article-title":"Neuroblastoma: developmental biology, cancer genomics and immunotherapy","volume":"13","author":"Cheung","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1038\/nrdp.2016.78","article-title":"Neuroblastoma","volume":"2","author":"Matthay","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41698-024-00745-0","article-title":"Artificial intelligence-based morphologic classification and molecular characterization of neuroblastic tumors from digital histopathology","volume":"8","author":"Ramesh","year":"2024","journal-title":"NPJ Precis Oncol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1641407\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:41:54Z","timestamp":1768372914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1641407\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":20,"alternative-id":["10.3389\/fped.2025.1641407"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1641407","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"article-number":"1641407"}}